Biomarin Pharmaceutical Inc (BMRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomarin Pharmaceutical Inc (BMRN) has a cash flow conversion efficiency ratio of 0.027x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($168.11 Million) by net assets ($6.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BMRN market cap overview for the company's overall valuation and market capitalisation.
Biomarin Pharmaceutical Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Biomarin Pharmaceutical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biomarin Pharmaceutical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomarin Pharmaceutical Inc ranked by their cash flow conversion efficiency. Explore BMRN operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RENTOKIL INITIAL ADR/5
F:RTO
|
N/A |
|
Taiwan Mobile Co Ltd
TW:3045
|
0.110x |
|
SINGAPORE EX.UNSP.ADR/15
F:SOUU
|
N/A |
|
China Gold International Resources
TO:CGG
|
0.108x |
|
WH GROU LTD SP.ADR /20
F:0WHS
|
N/A |
|
NortonLifeLock Inc
F:SYM
|
0.232x |
|
CENTRICA ADR NEW 2004/4
F:CENN
|
N/A |
|
Yara International ASA
OL:YAR
|
0.057x |
Annual Cash Flow Conversion Efficiency for Biomarin Pharmaceutical Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Biomarin Pharmaceutical Inc from 1998 to 2025. View Biomarin Pharmaceutical Inc (BMRN) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.09 Billion | $827.99 Million | 0.136x | +34.35% |
| 2024-12-31 | $5.66 Billion | $572.84 Million | 0.101x | +214.78% |
| 2023-12-31 | $4.95 Billion | $159.26 Million | 0.032x | -15.83% |
| 2022-12-31 | $4.60 Billion | $175.90 Million | 0.038x | -46.41% |
| 2021-12-31 | $4.27 Billion | $304.54 Million | 0.071x | +242.98% |
| 2020-12-31 | $4.11 Billion | $85.36 Million | 0.021x | +34.51% |
| 2019-12-31 | $3.12 Billion | $48.26 Million | 0.015x | +127.01% |
| 2018-12-31 | $2.97 Billion | $20.21 Million | 0.007x | +318.38% |
| 2017-12-31 | $2.81 Billion | $-8.76 Million | -0.003x | +96.21% |
| 2016-12-31 | $2.77 Billion | $-227.84 Million | -0.082x | +10.80% |
| 2015-12-31 | $2.40 Billion | $-221.69 Million | -0.092x | -91.85% |
| 2014-12-31 | $1.53 Billion | $-73.54 Million | -0.048x | -8.24% |
| 2013-12-31 | $1.34 Billion | $-59.63 Million | -0.044x | -356.51% |
| 2012-12-31 | $1.02 Billion | $17.61 Million | 0.017x | -28.54% |
| 2011-12-31 | $773.05 Million | $18.75 Million | 0.024x | -7.18% |
| 2010-12-31 | $717.26 Million | $18.75 Million | 0.026x | -90.40% |
| 2009-12-31 | $322.19 Million | $87.73 Million | 0.272x | +921.14% |
| 2008-12-31 | $276.68 Million | $-9.18 Million | -0.033x | +81.95% |
| 2007-12-31 | $187.73 Million | $-34.49 Million | -0.184x | +56.79% |
| 2006-12-31 | $117.80 Million | $-50.09 Million | -0.425x | -152.55% |
| 2005-12-31 | $-77.46 Million | $-62.68 Million | 0.809x | -15.56% |
| 2004-12-31 | $-67.98 Million | $-65.14 Million | 0.958x | +250.99% |
| 2003-12-31 | $117.85 Million | $-74.80 Million | -0.635x | -16.69% |
| 2002-12-31 | $98.54 Million | $-53.59 Million | -0.544x | -276.22% |
| 2001-12-31 | $159.55 Million | $-23.07 Million | -0.145x | +21.54% |
| 2000-12-31 | $69.99 Million | $-12.90 Million | -0.184x | -40.07% |
| 1999-12-31 | $98.38 Million | $-12.94 Million | -0.132x | +52.26% |
| 1998-12-31 | $29.40 Million | $-8.10 Million | -0.276x | -- |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more